Dinko Valerio

Dinko Valerio

Signal active

Co-Founder & Executive Chairman

Bio

Dinko Valerio is the current Co-Founder and Executive Chairman of Leyden Labs. He previously worked at AESCAP Venture as a Co-Founder and Managing Partner. Dinko Valerio attended Leiden University.

Location

Leiden, Zuid-Holland, The Netherlands, Europe

Social

Primary Organization

Leyden Labs

Leyden Labs

Founded

2020

Employees

51-100

Industry

Biotechnology, Life Science, Therapeutics

Jobs history

2

Leyden Labs

Co-Founder & Executive Chairman

2020 - Current

ProQR Therapeutics

Co-Founder and Chairman of the Board

2012 - Current

Board and Advisor Roles

0

N/A

Invest in regions

Profile Resume

Dinko Valerio is the Co-Founder & Executive Chairman at Leyden Labs, based in Europe. With a background in Biotechnology, Dinko Valerio has a rich history of leadership and innovation. Dinko Valerio studied Ph.D unknown @ Leiden University. Explore their detailed professional journey, key connections, and contributions to the industry on our platform.

Recommendation from your interest

Hans GCP Schikan

Hans GCP Schikan

Chief Executive Officer

Onno Stolpe

Onno Stolpe

CEO

John Maraganore

John Maraganore

CEO

David Meeker

David Meeker

Chairman, President & Chief Executive Officer

Edward Kaye

Edward Kaye

CEO & Founder

James Shannon

James Shannon

No designation

Investment portfolio

Dinko Valerio has made 2 investments. Their Latest investment was Seed Round - Xinvento on Apr 21, 2022

Number of investment

2

Number of exits

1

Personal investment

2

Annouced DateOrganization NameFunding RoundMoney Raised
May 14, 2018
PHYSEE Technologies PHYSEE Technologies
Venture Round - PHYSEE Technologies
1.8M
Apr 21, 2022
Xinvento Xinvento
Seed Round - Xinvento
0

Partner investment

2

Annouced DateOrganization NameFunding RoundInvestor NameMoney Raised
Oct 24, 2006
Affectis Pharmaceuticals Affectis Pharmaceuticals
Series C - Affectis Pharmaceuticals
Affectis Pharmaceuticals Aescap Venture
15.1M
Mar 22, 2010
Affectis Pharmaceuticals Affectis Pharmaceuticals
Series D - Affectis Pharmaceuticals
Affectis Pharmaceuticals Aescap Venture
4.5M

Exits

1

exit.name Xinvento

Xinvento

Xinvento provides a credible alternative treatment for congenital hyperinsulinism....

Invest in industries

Recent Activity

There is no recent news or activity for this profile.